Bora CDMO Bora CDMO

X

Find Drugs in Development News & Deals for Boswellia Serrata

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
45
INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

0

Europe

Europe

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

SERVICES

0

Details:

Through this partnership, and through HempStreet’s extensive distribution reach and key institutional partnerships, Indian patients will now have access to these medicines, starting with CimetrA (Artemisinin), which had an immediate need.


Lead Product(s): Artemisinin,Curcumin,Boswellia Serrata

Therapeutic Area: Infections and Infectious Diseases Product Name: CimetrA

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: MGC Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership May 07, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

MGC Pharma has secured this import license from CDSCO for CimetrA to enable it to submit final samples of CimetrA for testing and analysis. CimetrA is a nanoparticle micellar formulation based on a synergetic composition consisting of Curcumin and Boswellia.


Lead Product(s): Curcumin,Boswellia Serrata

Therapeutic Area: Infections and Infectious Diseases Product Name: CimetrA

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 02, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The Malta facility will create a European manufacturing hub for ArtemiCTM with the ability to scale production to meet expected growing demand following positive clinical trial results.


Lead Product(s): Artemisinin,Curcumin,Boswellia Serrata

Therapeutic Area: Infections and Infectious Diseases Product Name: ArtemiC

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Malta Enerprises

Deal Size: $3.7 million Upfront Cash: $3.7 million

Deal Type: Funding December 22, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY